Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.

307Background: Gemcitabine combined with cisplatin (GP) has been established as the standard first-line treatment in patients with unresectable biliary tract cancers (BTC), a heterogeneous group of...